Premium
Durable remission of both multicentric Castleman's disease and Kaposi's sarcoma with valganciclovir, rituximab and liposomal doxorubicin in an HHV ‐8‐positive, HIV ‐negative patient
Author(s) -
Murphy C.,
Hawkes E.,
Chionh F.,
Chong G.
Publication year - 2017
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12472
Subject(s) - medicine , rituximab , doxorubicin , sarcoma , valganciclovir , kaposi's sarcoma , human immunodeficiency virus (hiv) , chemotherapy , oncology , surgery , virology , human herpesvirus , pathology , virus , lymphoma , human cytomegalovirus , cytomegalovirus infection
Summary What is known and objective Human herpesvirus‐8 ( HHV ‐8)‐positive, HIV ‐negative multicentric Castleman's disease is a rare lymphoproliferative disorder with no standardized treatment. Concurrent Kaposi's sarcoma, another HHV ‐8‐related disease, is uncommon in HIV ‐negative patients. The role of antiviral therapy and rituximab in HIV ‐negative patients is not well established. Case description We report a case of a 5‐year, durable remission of HHV ‐8‐positive, HIV ‐negative comorbid multicentric Castleman's disease and Kaposi's sarcoma treated with long‐term valganciclovir, following initial rituximab and liposomal doxorubicin. What is new and conclusion Currently, there is no defined role for antiviral therapy in the treatment of HIV ‐negative HHV ‐8‐positive multicentric Castleman's disease and Kaposi's sarcoma. Ganciclovir followed by indefinite, continuous valganciclovir is thought to have contributed significantly to the durable response in this case.